Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MIRM with free AI briefings, catalyst countdowns, and dilution alerts.

MIRM · Mirum Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$669.9M Cash on Hand
82.8mo Cash Runway
12.8% Short Interest
$157.71 Analyst Target (13)
Follow MIRM by email Get an email when MIRM reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MIRM, unsubscribe in one click. Privacy

📣 What MIRM Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Maralixibat
FDA approved Sep 2021 · Livmarli
Alagille Syndrome Phase 4 · NCT07290257 Recruiting
Cholic Acid
FDA approved Mar 2015 · Cholbam
Bile Acid Synthesis Defect Phase 3 · NCT01438411 Completed
Blinded CDCA 250 mg TID CTX Phase 3 · NCT04270682 Completed
Brelovitug Chronic Hepatitis D Phase 2/3 · NCT07454837 Recruiting
CDCA Weight-Based Dose TID CTX Phase 3 · NCT04270682 Completed
Rescue Medication CDCA 250 mg TID CTX Phase 3 · NCT04270682 Completed
Open-Label CDCA 250 mg TID CTX Phase 3 · NCT04270682 Completed
LUM001 Progressive Familial Intrahepatic Cholestasis (PFIC) Phase 2 · NCT02057718 Completed
Volixibat Primary Biliary Cholangitis Phase 2 · NCT05050136 Active not recruiting
Middle Dose of MRM-3379 Fragile X Syndrome Phase 2 · NCT07209462 Recruiting
Ursodiol PBC Phase 2 · NCT01904058 Completed
Low dose of MRM-3379 Open-Label Fragile X Syndrome Phase 2 · NCT07209462 Recruiting
High dose of MRM-3379 Fragile X Syndrome Phase 2 · NCT07209462 Recruiting
[14C]-MRM-3379 Healthy Volunteers Phase 1 · NCT07712718 Completed

Also used in these trials (approved or third-party drugs, not MIRM's own candidates): Bulevirtide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MIRM holds $669.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.3M/quarter from operations, an estimated runway of 82.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MIRM files for a raise →

👥 Who Owns MIRM

Insiders 7.5% Other 5%+ holders 5.7% Institutions (453 holders) 86.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Frazier Life Sciences Management, L.P. Institution (13F) 7,679,684 11.76% 2026-09-30
JANUS HENDERSON GROUP Ltd. Institution (13G, 5%+) 5,537,330 8.48% 2026-09-30
Patrick J Heron
Director · +5,752 options
Insider 4,031,625 6.18% 2026-01-23
FMR LLC Institution (13G, 5%+) 3,777,851 5.79% 2026-06-30
James N. Topper 5%+ holder (13D) 3,735,220 5.72% 2025-11-01
BlackRock, Inc. Institution (13G, 5%+) 3,465,559 5.31% 2026-03-31
Vanguard Portfolio Management LLC Institution (13F) 2,633,578 4.03% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 2,544,392 3.90% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 2,498,555 3.83% 2026-09-30
State Street Corporation Institution (13F) 2,390,681 3.66% 2026-09-30
Wellington Management Group, LLP Institution (13F) 1,688,453 2.59% 2026-09-30
Invesco Ltd. Institution (13F) 1,534,501 2.35% 2026-09-30

Share count 65,282,044 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-11
filed 2026-11-13
Brege Laura
Option exercise (M) 14,167 $16.71 29,870
2026-11-11
filed 2026-11-13
Brege Laura
Sale (S) 10,907 $94.05 18,963
2026-11-11
filed 2026-11-13
Brege Laura
Sale (S) 3,260 $94.74 15,703
2026-11-11
filed 2026-11-13
Brege Laura
Option exercise (M) 14,167 – –
2026-11-04
filed 2026-11-04
Peetz Christopher
Option exercise (M) 20,000 $2.94 226,637

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-09-26 Atebrioz (zilurgisertib) NDA -8.9% — —

Browse all historical PDUFA outcomes →

Get the full MIRM picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MIRM and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.